Ceribell Raises Full-Year Revenue Guidance, Reports 29% Q1 Growth to $26.5M
CBLL sits 85% above its 52-week low of $10.85.
Summary
Ceribell reported strong first-quarter 2026 financial results, with total revenue increasing 29% year-over-year to $26.5 million. The company also raised its full-year 2026 revenue guidance to a range of $112 million to $116 million, representing 26% to 30% growth. While net loss widened to $19.7 million ($0.52 per share) due to a 36% increase in operating expenses, management attributed this to investments in commercial organization, headcount, and legal costs. Operational highlights include the commercial launch of neonate and pediatric products and a supportive CMS proposed rule for NTAP reimbursement for its delirium monitoring solution. This positive guidance update and robust revenue growth are significant for a growth-oriented medical technology company, signaling strong demand and execution despite increased investment.
At the time of this announcement, CBLL was trading at $20.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $759.7M. The 52-week trading range was $10.85 to $24.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.